Moriarity Andrew, O'Sullivan Jacintha, Kennedy John, Mehigan Brian, McCormick Paul
St James's Hospital, Surgical Oncology, St James's St, Dublin 8, Ireland.
St James's Hospital, Dublin, Ireland.
Ther Adv Med Oncol. 2016 Jul;8(4):276-93. doi: 10.1177/1758834016646734. Epub 2016 May 29.
Treatment strategies for metastatic colorectal cancer (mCRC) patients have undergone dramatic changes in the past decade and despite improved patient outcomes, there still exist areas for continued development. The introduction of targeted agents has provided clinicians with additional treatment options in mCRC, however, results have been mixed at best. These novel therapies were designed to interfere with specific molecules involved in the cellular carcinogenesis pathway and ultimately deliver a more focused treatment. Currently, their use in mCRC has been limited primarily as an adjunct to conventional chemotherapy regimens. This review explores the relevant cell-signaling networks in colorectal cancer, provides focus on the current targeted agent armamentarium approved for use in mCRC and explores the usefulness of predictive mCRC biomarkers.
在过去十年中，转移性结直肠癌（mCRC）患者的治疗策略发生了巨大变化。尽管患者预后有所改善，但仍有持续发展的空间。靶向药物的引入为临床医生提供了mCRC的额外治疗选择，然而，其结果充其量也参差不齐。这些新型疗法旨在干扰细胞致癌途径中涉及的特定分子，最终实现更有针对性的治疗。目前，它们在mCRC中的应用主要限于作为传统化疗方案的辅助手段。本综述探讨了结直肠癌相关的细胞信号网络，重点关注目前批准用于mCRC的靶向药物库，并探讨预测性mCRC生物标志物的实用性。
